336,847 Shares in AxoGen, Inc. $AXGN Bought by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC purchased a new position in AxoGen, Inc. (NASDAQ:AXGN) during the 4th quarter, Holdings Channel.com reports. The firm purchased 336,847 shares of the medical equipment provider’s stock, valued at approximately $11,025,000.

Other large investors also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in AxoGen by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,185 shares of the medical equipment provider’s stock worth $466,000 after buying an additional 1,057 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of AxoGen by 7.1% during the second quarter. The Manufacturers Life Insurance Company now owns 16,194 shares of the medical equipment provider’s stock valued at $176,000 after purchasing an additional 1,079 shares during the period. Arizona State Retirement System boosted its stake in shares of AxoGen by 10.0% during the third quarter. Arizona State Retirement System now owns 12,801 shares of the medical equipment provider’s stock valued at $228,000 after purchasing an additional 1,164 shares during the period. Mercer Global Advisors Inc. ADV boosted its stake in shares of AxoGen by 11.7% during the third quarter. Mercer Global Advisors Inc. ADV now owns 11,193 shares of the medical equipment provider’s stock valued at $200,000 after purchasing an additional 1,173 shares during the period. Finally, Aquatic Capital Management LLC boosted its stake in shares of AxoGen by 287.8% during the third quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 1,269 shares during the period. Institutional investors own 80.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Wall Street Zen lowered shares of AxoGen from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Raymond James Financial reissued an “outperform” rating and set a $48.00 target price on shares of AxoGen in a research note on Wednesday, April 29th. Citigroup reissued an “outperform” rating on shares of AxoGen in a research note on Wednesday, April 29th. Zacks Research lowered shares of AxoGen from a “hold” rating to a “strong sell” rating in a research note on Monday, April 27th. Finally, Canaccord Genuity Group boosted their target price on shares of AxoGen from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Nine analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $46.50.

AxoGen Stock Performance

AXGN stock opened at $42.69 on Wednesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.10 and a quick ratio of 5.33. The business has a 50-day moving average price of $35.97 and a 200 day moving average price of $32.45. The company has a market capitalization of $2.27 billion, a P/E ratio of -66.70 and a beta of 1.17. AxoGen, Inc. has a 1-year low of $9.22 and a 1-year high of $45.83.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.05). The firm had revenue of $61.46 million during the quarter, compared to the consensus estimate of $57.85 million. AxoGen had a negative net margin of 13.21% and a negative return on equity of 9.63%. As a group, equities research analysts forecast that AxoGen, Inc. will post -0.3 EPS for the current fiscal year.

Insider Transactions at AxoGen

In related news, Director Kathy Johnson Weiler sold 16,344 shares of AxoGen stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $44.09, for a total value of $720,606.96. Following the completion of the sale, the director directly owned 16,344 shares in the company, valued at $720,606.96. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director John Johnson sold 11,050 shares of AxoGen stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $43.26, for a total value of $478,023.00. Following the completion of the sale, the director owned 11,050 shares of the company’s stock, valued at $478,023. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 34,262 shares of company stock valued at $1,440,250. Insiders own 2.44% of the company’s stock.

AxoGen Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.